Vertex Pharmaceuticals Incorporated (VRTX)

350.63 -0.53 (-0.15%) At close: 04:00PM EST

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617 341 6100
https://www.vrtx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 4,800

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jeffrey Marc Leiden M.D., Ph.D.	Executive Chairman	92.93k	11.49M	1956
Dr. Reshma Kewalramani FASN, M.D.	CEO, President & Director	5.22M	N/A	1973
Mr. Charles F. Wagner Jr.	Executive VP & CFO	2.06M	N/A	1968
Mr. Stuart A. Arbuckle B.Sc.	Executive VP & COO	2.7M	1.26M	1966
Dr. David M. Altshuler M.D., Ph.D.	Executive VP of Global Research & Chief Scientific Officer	2.03M	3.09M	1965
Ms. Kristen C. Ambrose	Senior VP & Chief Accounting Officer	N/A	N/A	1977
Mr. Mike Tirozzi	SVP and Chief Information & Data Officer	N/A	N/A	N/A
Susie Lisa	Senior Vice President of Investor Relations	N/A	N/A	N/A
Mr. Damian W. Wilmot Esq.	Senior VP, Chief Risk and Compliance Officer	N/A	N/A	1976
Mr. Jonathan Biller J.D.	Executive VP & Chief Legal Officer	N/A	N/A	1964

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Corporate governance

Vertex Pharmaceuticals Incorporated’s ISS governance QualityScore as of 1 December 2023 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.